A comparative randomized study for the evaluation of the overlaying effect of Selegiline or Zonisamide over Levodopa in Parkinson's disease
- Conditions
- Parkinson's disease
- Registration Number
- JPRN-UMIN000022533
- Lead Sponsor
- Osaka Redcross Hospital Wakayama Prefectural Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 180
Not provided
Those who matched the following conditions should be excluded. 1). Those who had been treated with the anti-parkinsonian drugs except levodopa/DCI for more than 1month. 2).Those who are in pregnancy, or possible to be pregnant or those who are in the breast-feeding. 3) Those who have taken antidepressant and/or anti-psychotic drugs. 4) Those who have a history of stroke and cerebrovascular disorders. 5) Those who had a history of epilepsy or those who are in treatment of epilepsy 6) Those who have a history of alcohol intoxication, or have the treatment for alcoholic abuse 7) Those who have severe comorbidity( liver dysfunction, renal dysfunction and endocrinological disorders). 8) Those who have a familial history of Parkinson's disease 9) Those who have a history of allergic reaction with 123I- ioflupane.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The neuroprotective effect is evaluated by 123I-FP-CIT SPECT after 1 year.
- Secondary Outcome Measures
Name Time Method The clinical symptoms are evaluated by UPDRS partII, UPDRS partIII, PDQ-39